Lookup NU author(s): Professor John Isaacs
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
An expanding range of biological therapies is available for patients with rheumatoid arthritis. Clinical trials and real-life experience demonstrate significant interpatient heterogeneity in efficacy as well as important adverse effects of these treatments. In order to maximise their benefit: risk ratios and to minimise later joint damage, we need to define predictors of response and, ideally, of adverse effects for each of these drugs. There is huge interest in this field of 'personalised medicine', which should allow us to optimally match patient with treatment, providing the parallel benefit of reduced treatment costs. In this short article the current state of the art for licensed biological therapies is summarised. There have been some noteworthy discoveries but the challenge is now to design studies to confirm and validate these findings while also devising large, potentially international, collaborations to identify additional, robust biomarkers that predict outcome.
Author(s): Isaacs JD, Ferraccioli G
Publication type: Article
Publication status: Published
Journal: Annals of the Rheumatic Diseases
Print publication date: 10/11/2010
ISSN (print): 0003-4967
ISSN (electronic): 1468-2060
Publisher: BMJ Group
Altmetrics provided by Altmetric